178 related articles for article (PubMed ID: 30579570)
21. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib and rituximab for chronic lymphocytic leukaemia.
Stirrups R
Lancet Oncol; 2019 Sep; 20(9):e471. PubMed ID: 31402323
[No Abstract] [Full Text] [Related]
23. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
24. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
25. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
[No Abstract] [Full Text] [Related]
26. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
Krämer I; Stilgenbauer S; Dietrich S; Böttcher S; Zeis M; Stadler M; Bittenbring J; Uharek L; Scheid C; Hegenbart U; Ho A; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P
Blood; 2017 Sep; 130(12):1477-1480. PubMed ID: 28716861
[No Abstract] [Full Text] [Related]
27. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Wierda WG; Byrd JC; O'Brien S; Coutre S; Barr PM; Furman RR; Kipps TJ; Burger JA; Stevens DA; Sharman J; Ghia P; Flinn IW; Zhou C; Ninomoto J; James DF; Tam CS
Br J Haematol; 2019 Jul; 186(1):184-188. PubMed ID: 30740654
[No Abstract] [Full Text] [Related]
28. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
29. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.
Montillo M; O'Brien S; Tedeschi A; Byrd JC; Dearden C; Gill D; Brown JR; Barrientos JC; Mulligan SP; Furman RR; Cymbalista F; Plascencia C; Chang S; Hsu E; James DF; Hillmen P
Blood Cancer J; 2017 Feb; 7(2):e524. PubMed ID: 28157216
[No Abstract] [Full Text] [Related]
30. The use of ibrutinib in chronic lymphocytic leukemia.
Damon LE
Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
[No Abstract] [Full Text] [Related]
31. Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.
Tavitian S; Peron JM; Huguet F; Kamar N; Abravanel F; Beyne-Rauzy O; Oberic L; Faguer S; Alric L; Roussel M; Gaudin C; Ysebaert L; Huynh A; Recher C
Emerg Infect Dis; 2015 Aug; 21(8):1466-9. PubMed ID: 26197210
[TBL] [Abstract][Full Text] [Related]
32. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
33. Ibrutinib for Chronic Lymphocytic Leukemia.
Ruchlemer R; Ben Ami R; Lachish T
N Engl J Med; 2016 Apr; 374(16):1593-4. PubMed ID: 27096597
[No Abstract] [Full Text] [Related]
34. Ibrutinib for Chronic Lymphocytic Leukemia.
Rigolin GM; Cavazzini F; Cuneo A
N Engl J Med; 2016 Apr; 374(16):1593. PubMed ID: 27096596
[No Abstract] [Full Text] [Related]
35. Ibrutinib for Chronic Lymphocytic Leukemia.
Sharman JP; Mato AR; Keating MJ
N Engl J Med; 2016 Apr; 374(16):1592-3. PubMed ID: 27096595
[No Abstract] [Full Text] [Related]
36. Ibrutinib for Chronic Lymphocytic Leukemia.
Burger JA; Styles L; Kipps TJ
N Engl J Med; 2016 Apr; 374(16):1594-5. PubMed ID: 27096594
[No Abstract] [Full Text] [Related]
37. Ibrutinib-Induced Lymphocytosis: Cytological Features.
Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
[No Abstract] [Full Text] [Related]
38. Ribavirin treatment of a patient with chronic hepatitis E. First case reported in Latin America.
Gruz F; Munné MS; González J; Lizarraga Villagran MA; Raffaele PP; Descalzi VI
Acta Gastroenterol Latinoam; 2016 Jun; 46(2):122-5. PubMed ID: 28704018
[TBL] [Abstract][Full Text] [Related]
39. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
Tucker DL; Mihailescu L; Riordan R; Rule S
Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457
[No Abstract] [Full Text] [Related]
40. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
